reports
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Inves...
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq in New York, NY on Tuesday, May 20, 2025. Management will also be available for one-on-one meetings....
BioCryst Presents New Real-world Evidence Showing Significant and Sust...
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations. The real-w...
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
GOGO GOGO INC.
ERII ENERGY RECOVERY INC.
ELY CALLAWAY GOLF COMPANY
GCBC GREENE COUNTY BANCORP INC.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
PMTS INC.
PNBK CPI CARD GROUP
EAF PATRIOT NATIONAL BANCORP
ULBI GRAFTECH INTERNATIONAL
ENR ULTRALIFE
PHAT EDGEWELL PERSONAL CARE COMPANY
LPI PHATHOM PHARMACEUTICALS
LESL LAREDO PETROLEUM INC.
MYO LESLIES
FLNC MYOMO
DCGO FLUENCE ENERGY INC
OGN DOCGO INC
TCBX ORGANON & CO
OABI THIRD COAST BANCSHARES INC
WEST OMNIAB INC
SRPT WESTROCK COFFEE COMPANY LLC
FTK SAREPTA THERAPEUTICS
BNL INC.
DMA FLOTEK INDUSTRIES INC.
SUNS BROADSTONE NET LEASE INC
EVM DESTRA MULTI ALTERNATIVE FUND
TXO SUNRISE REALTY TRUST
FG EATON VANCE INSD CALIF MUN BD FD
EU MORNINGSTAR PARTNERS
IAE L.P.
AESI F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
ATLAS ENERGY SOLUTIONS INC.
Applied Optoelectronics Inc: 3 directors
Three Directors at Applied Optoelectronics Inc bought/sold/sold after exercising options 56,463 shares at between 18.218USD and 19.098USD. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretion...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
LTRX LANTRONIX INC.
BRKR BRUKER CORPORATION
OFIX ORTHOFIX INTERNATIONAL N.V.
NEWT NEWTEK BUSINESS SERVICES INC.
HTLD HEARTLAND EXPRESS INC.
THS TREEHOUSE FOODS INC.
WINA WINMARK CORP.
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
HAIN INC.
SNBR THE HAIN CELESTIAL GROUP
LILA INC.
COLD SLEEP NUMBER CORPORATION
ULBI LIBERTY LATIN AMERICA A
MIDD AMERICOLD REALTY TRUST
CCO ULTRALIFE
PRG THE MIDDLEBY CORPORATION
LESL CLEAR CHANNEL OUTDOOR HOLDINGS INC
KLXE PROG HOLDINGS
CVRX INC.
MYO LESLIES
SEAT KLX ENERGY SERVICES
DCGO CVRX
PFHC INC.
MYOMO
VIVID SEATS INC.
DOCGO INC
PROFRAC HLDG CORP
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) ...
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years –FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– –ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the age of 12, if approved– RESEARCH TRIANGLE PARK, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for the use of oral, once-daily ORLADEYO® (be...
Humacyte Announces First Quarter 2025 Financial Results and Provides B...
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - Completed public offering raising $46.7 million in net proceeds - - Implemented cost reduction to extend cash runway - ---Conference call today at 8:30am ET - DURHAM, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stag...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
BZH BEAZER HOMES USA INC.
ASB ASSOCIATED BANC-CORP
APLE APPLE HOSPITALITY REIT INC
OFIX ORTHOFIX INTERNATIONAL N.V.
THS TREEHOUSE FOODS INC.
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
HAIN THE HAIN CELESTIAL GROUP
CARS INC.
PMTS CARS.COM INC.
BLDR CPI CARD GROUP
CCO BUILDERS FIRSTSOURCE
RYES INC.
MTCH CLEAR CHANNEL OUTDOOR HOLDINGS INC
CIVI PATRIOT MINEFINDERS INC.
NVCT MATCH GROUP INC.
MAIA CIVITAS RESOURCES INC
VSTS_w NUVECTIS PHARMA INC
BNL MAIA BIOTECHNOLOGY INC
DMA VESTIS CORPORATION
FG BROADSTONE NET LEASE INC
DESTRA MULTI ALTERNATIVE FUND
F AND G ANNUITIES AND LIFE
INC.
Applied Optoelectronics Announces Equity Grants To Employees Under Ind...
Applied Optoelectronics Announces Equity Grants To Employees Under Inducement Plan SUGAR LAND, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced that the Compensation Committee of its Board of Directors granted inducement awards for 11,860 shares of common stock to 5 new employees, with a grant date of May 9, 2025, pursuant to the Applied Optoelectronics, Inc. 2023 Equity Inducement Plan (t...
Humacyte to Present First Quarter Financial Results and Provide Corpor...
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to provide a corporate and financial update. Title:Humacyte First Quarter 2025 Financial Results and Corporate UpdateDat...
Applied Optoelectronics Reports First Quarter 2025 Results
Applied Optoelectronics Reports First Quarter 2025 Results SUGAR LAND, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Applied Optoelectronics, Inc. (NASDAQ: AAOI) (“AOI”), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced financial results for its first quarter ended March 31, 2025. “We’re pleased to deliver results that were in line with or better than our expectations,” said Dr. Thompson Lin, AOI’s Founder, President and Chief Executive Officer. “We continue to see strong demand...
Genelux Corporation Reports First Quarter 2025 Financial Results and P...
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates. “The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase ...
- Dylan Shindler
- Laura Chico
BioCryst Reports First Quarter 2025 Financial Results and Provides Bus...
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update —Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome— RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOB...
- Wedbush Research
UDR UDR INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
GERN GERON CORP.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
CPT CAMDEN PROPERTY TRUST
CNK CINEMARK HOLDINGS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AVB AVALONBAY COMMUNITIES INC.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
VICI VICI PROPERTIES INC
APLS APELLIS PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
RCUS ARCUS BIOSCIENCES
PEAK HEALTHPEAK PROPERTIES INC.
RVMD REVOLUTION MEDICINES
CRSR CORSAIR GAMING
PRAX PRAXIS PRECISION MEDICINES
FUBO FUBOTV
RKT ROCKET COMPANIES
CSR CENTERSPACE
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
NTST NETSTREIT CORP
VIGL VIGIL NEUROSCIENCE INC
HR HEALTHCARE TRUST OF AMERICA INC.
SYRE SPYRE THERAPEUTICS INC.
BNL BROADSTONE NET LEASE INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
RARE ULTRAGENYX PHARMACEUTICAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
GERN GERON CORP.
BCRX BIOCRYST PHARMACEUTICALS INC.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
RVMD REVOLUTION MEDICINES
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
XPL SOLITARIO ZINC
RGP RESOURCES CONNECTION INC.
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
LPG DORIAN LPG
WHF WHITEFIELD
AMTX AEMETIS
GCBC GREENE COUNTY BANCORP INC.
JFR NUVEEN FLOATING RATE INCOME FUND
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
DOMO DOMO INCORPORATED
BCDA BIOCARDIA
PCB PACIFIC CITY FINANCIAL CORP
ASAN ASANA
PCVX VAXCYTE
WOOF PETCO HEALTH AND WELLNESS
NUVB NUVATION BIO INC (A)
CTGO CONTANGO ORE INC.
SMMT SUMMIT THERAPEUTICS INC
HUMA HUMACYTE INC
TCBX THIRD COAST BANCSHARES INC
PEPG PEPGEN INC
GLSI GREENWICH LIFESCIENCES INC
JMSB JOHN MARSHALL BANCORP INC
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
NMTC NEUROONE MEDICAL TECHNOLOGIES CORP
SSII SS INNOVATIONS INTERNATIONAL INC
CATX PERSPECTIVE THERAPEUTICS
DMA INC.
SUNS DESTRA MULTI ALTERNATIVE FUND
NUTX SUNRISE REALTY TRUST
AFCG NUTEX HEALTH INC
FTLF AFC GAMMA
INC.
FITLIFE BRANDS INC.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 48,000 shares of BioCryst common stock. The RSUs were granted as of May 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual i...
Genelux Corporation to Participate in a Fireside Chat at the Citizens ...
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board, and , CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursd...
BioCryst Appoints Steve Frank to Board of Directors
BioCryst Appoints Steve Frank to Board of Directors RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnolog...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.